Global Predictive and Presymptomatic Testing Market

The Predictive and Presymptomatic Testing Market size was valued at USD 5.08 Billion in 2023 and the total Predictive and Presymptomatic Testing revenue is expected to grow at a CAGR of 9.6% from 2024 to 2030, reaching nearly USD 9.66 Billion.

The global Predictive and Presymptomatic Testing Market report is a comprehensive analysis of the industry, market, and key players. The report has covered the market by demand and supply-side by segments. The global Predictive and Presymptomatic Testing Market report also provides trends by market segments, technology, and investment with a competitive landscape.

Global Predictive and Presymptomatic Testing Market Overview:

Presymptomatic testing (PST) is a genetic test carried out on an individual that has no irregular symptoms or an asymptomatic individual to determine whether the person has a hereditary disease-causing mutation or any genetic disorders that can lead to genetic disorders in the future. Further, this test is carried out to identify whether a person will develop a genetic disorder in the future or not and reduce the rising occurrence of genetic disorders. Predictive genetic testing is the use of a genetic test in an asymptomatic person to predict future risk of disease. These tests represent a new and growing class of medical tests, differing in fundamental ways from conventional medical diagnostic tests.

To know about the Research Methodology :- Request Free Sample Report

Global Predictive and Presymptomatic Testing Market Dynamics:

The predictive and presymptomatic testing market expected to grow at CAGR of 9.6% during the forecast year of 2024-2030 due to growing genetic disorders and genetic counseling. Resources and technological advancement have played a great role in genetic counseling. As per medical conditions, 10% of individuals are suffering from genetic defects, however, it's a minor disease. Some of the common genetic disorders are Down syndrome, Thalassemia, Cystic fibrosis, sickle cell anemia, and various others.

As per Proceeding National Academy of Science of North America, around 2.7 billion people (36% of the total world population) worldwide are the carrier of at least one mutation that causes AR-IRD that is autosomal recessive (AR) inherited retinal diseases (IRDs). Moreover, modern technologies and the latest innovations concerning genetic disorders are boosting the market growth of the predictive and presymptomatic testing market. Also, there is no cure for genetic disorders; they can only be treated and not cured fully.

Global Predictive and Presymptomatic Testing Market Segment Analysis:

By Condition, the segment is divided into Breast and Ovarian Cancer, Colorectal Cancer, Alzheimer’s disease, Multiple Endocrine Neoplasia Type – 2, Haemochromatosis. Breast and Ovarian Cancer is dominating the conditioning segment of the Predictive and Presymptomatic Testing market and is estimated to witness the highest CAGR in the forecast period of 2024-2030. Cancers included in the conditioning segment are not genetic disorders but are greatly controlled by genes in the body and are passed from one generation to another. The identification of BRCA1 and BRCA that Breast Cancer Gene in 1994-1995 leads to the testing of presymptomatic DNA testing for autosomal dominant hereditary breast and ovarian cancer.

Every healthy mutation carrier of the BRCA gene has a high risk of breast cancer and ovarian cancer for a lifetime. Moreover, India and America are the countries where women are highly suffered from breast cancer every year. In India, the total number of breast cancer frequency cases was valued at 7,12,758 in 2020 and estimated to reach 8,06,218 by 2025 in women. The number of breast cancer cases that is 2,38,908 is expected to be the most common cancer forecast period, followed by cancer in the lung (1,11,328) and mouth (90,060) in the future.

Additionally, around 2.3 million breast cancer cases were reported in women and 685000 deaths were caused due to breast cancer globally in the year 2020. Further, the rate has decreased due to high technological investments and precise medications with advanced therapy like oral chemotherapy and a target drug delivery system.

Global Predictive and Presymptomatic Testing Market Regional Insights:

North America is dominating the predictive and presymptomatic testing market regional insight. The major countries of North America are the US, Mexico, and Canada. Among these, the US was valued at USD 1.12 billion in the year 2020. In 2020, an estimated 276,480 new cases of proliferating breast cancer were diagnosed in women in the U.S. 65% of breast cancer cases are diagnosed at a localized stage, in which 5-year survival is 98%. Additionally, North America is ranked highest in breast cancer treatment due to the occurrence of breast cancer cases in women. Further, the high technological investment in the region with growing healthcare facilities with advanced infrastructure are fuelling the market growth of predictive and presymptomatic testing in the regional market.

The objective of the report is to present a comprehensive analysis of the global Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.

PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding the global Market dynamics, structure by analyzing the market segments and project the global Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the global Market make the report investor’s guide.

Global Predictive and Presymptomatic Testing Market Scope: Inquire before buying

Global Predictive and Presymptomatic Testing Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Global Predictive and Presymptomatic Testing Market Key Player

1. 23andMe, Inc.
2. Abbott Molecular, Inc.
3. BioAxis DNA Research Centre Private Limited
4. Color Genomics, Inc.
5. Direct Laboratory Services LLC (DirectLabs)
6. Gene by Gene Ltd.
7. Genomic Diagnostics
8. Mapmygenome
9. Myriad Genetics, Inc.
10. Pathway Genomics Corporation
11. Positive Bioscience, Inc.
12. Quest Diagnostics, Inc
Frequently Asked Questions:

1. Which region has the largest share in Global Predictive and Presymptomatic Testing Market?
Ans: North America region held the highest share in 2023.

2. What was the Global Predictive and Presymptomatic Testing Market size in 2023?
Ans: The Global Predictive and Presymptomatic Testing Market size was USD 5.08 Billion in 2023.

3. What is scope of the Global Predictive and Presymptomatic Testing Market report?
Ans: Global Predictive and Presymptomatic Testing Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Predictive and Presymptomatic Testing Market?
Ans: The important key players in the Global Xyz Market are – 23andMe, Inc., Abbott Molecular, Inc., BioAxis DNA Research Centre Private Limited, Color Genomics, Inc., Direct Laboratory Services LLC (DirectLabs), Gene by Gene Ltd., Genomic Diagnostics, Mapmygenome, Myriad Genetics, Inc., Pathway Genomics Corporation, Positive Bioscience, Inc., Quest Diagnostics, Inc.

5. What is the study period of this Market?
Ans: The Global Predictive and Presymptomatic Testing Market is studied from 2023 to 2030.